“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” said Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
‘Anticompetitive Scheme?’: Tyson Foods Faces Missouri Antitrust Class Action in Chicken Plant Dispute
“Defendants’ anticompetitive conduct has restrained competition for the purchase of
